Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Italy

CMS Adonnino Ascoli & Cavasola Scamoni has developed a broad expertise in the field of life sciences. The firm's life sciences practice includes the assistance of clients which operate in the fields of pharmaceuticals, biotechnology medical devices and more generally health care services. We regularly advise life science companies on corporate governance matters and licensing and contracts, as well as day-to-day corporate issues. The Team can count on professionals “borrowed” on a regular basis, to life sciences from other departments of the firm including team of corporate and intellectual property professionals who can boast a significant experience securing and defending patent positions and regulatory law issues in order for companies to comply with the Italian regulatory law.

Read more Read less

Choose area

    Pharmaceuticals

    Today the pharmaceutical industry is rapidly growing. This is a highly complex industry and represents one of the fastest growing on the market.

    Read more

    Feed

    Show only
    09/04/2019
    CMS al fianco della so­ci­età belga Medi-Mar­ket S.A....
    15 Nov 19
    Brexit and data pro­tec­tion: what to do next (when you don’t know what’s...
    Whilst the threat of a no-deal Brexit has been aver­ted for now, the fu­ture is by no means cer­tain. We have high­lighted some of the key is­sues for UK-based or­gan­isa­tions, and the EEA or­gan­isa­tions that...
    06/03/2019
    The European Com­mis­sion sets new rules for the qual­ity...
    05 Nov 19
    Whis­tleblow­ing Dir­ect­ive ad­op­ted by the EU Coun­cil
    On 7 Oc­to­ber 2019, the EU Coun­cil ap­proved the word­ing of the "Dir­ect­ive of the European Par­lia­ment and of the Coun­cil on the pro­tec­tion of per­sons who re­port breaches of Uni­on law", also known as the...
    01/02/2019
    Get­ting the Deal Through – Life Sci­ences 2019
    13 Sep 19
    SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
    Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...
    06/06/2018
    European Com­mis­sion pro­poses SPC ex­emp­tions for gen­er­ics...
    13 Jun 19
    SPC Man­u­fac­tur­ing Waiver to come in­to ef­fect 1 Ju­ly 2019
    Gen­er­ics com­pan­ies will soon be able to man­u­fac­ture SPC-pro­tec­ted drugs for ex­port out­side the EU un­der new man­u­fac­tur­ing waiver pro­vi­sions. In the last six months of the SPC life­time, it will also be...
    01/02/2018
    Get­ting the Deal Through - Life Sci­ences 2018
    30 May 19
    EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from...
    The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc.'s European pat­ent ap­plic­a­tion (EP07837908.8), the claimed chem­ic­al...
    11/01/2017
    Get­ting the Deal Through – Life Sci­ences 2017
    27 Mar 19
    Judg­ment on Ab­rax­is C-443/17; 21st March 2019
    The CJEU de­livered its judg­ment last week on the case of Ab­rax­is v Comp­troller Gen­er­al of Pat­ents con­cern­ing Sup­ple­ment­ary Pro­tec­tion Cer­ti­fic­ates (SPCs) for new for­mu­la­tions of medi­cin­al products. The...